Skip to main content


Latest articles

20-09-2019 | Rheumatology | News | Article

Multiple modifiable risk factors impact post hip replacement dislocation risk

Dislocation risk following total hip replacement is declining with time and is associated with a number of surgical, hospital, and patient-related factors that are generally modifiable, UK researchers report.

19-09-2019 | Rheumatology | News | Article

IL-1 inhibition may benefit for people with RA, type 2 diabetes

Treatment with the interleukin-1 inhibitor anakinra improves both glycemic and inflammatory endpoints among patients with rheumatoid arthritis and type 2 diabetes, suggest findings from the TRACK trial.

18-09-2019 | Rheumatology | News | Article

Ustekinumab efficacious in TNF-inhibitor naïve PsA patients

Ustekinumab elicits a greater clinical response versus placebo in patients with psoriatic arthritis naïve to tumor necrosis factor inhibitors, regardless of prior conventional synthetic DMARD or methotrexate exposure, PSUMMIT 1 and PSUMMIT 2 study data show.

17-09-2019 | Rheumatology | Highlight | Article

Global RA burden ‘significant, yet under-recognized’

Almost 20 million people worldwide were living with rheumatoid arthritis in 2017, with over a million new cases diagnosed each year, according to estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study.

16-09-2019 | Rheumatology | News | Article

Early tight control strategy may not have long-term benefits for PsA patients

Follow-up results from the TICOPA study suggest no long-term clinical advantage of an early treat-to-target strategy for patients with psoriatic arthritis.

13-09-2019 | Rheumatology | Main feed | News

Long-term benefits of secukinumab demonstrated in ankylosing spondylitis

Findings from the MEASURE 1 extension study suggest that the IL-17A inhibitor secukinumab has consistent efficacy and safety profiles over 5 years among patients with ankylosing spondylitis.

12-09-2019 | Rheumatology | News | Article

Predictors of hip osteoarthritis progression identified

Comorbidity, Kellgren–Lawrence grade, superior or superolateral femoral head migration, and subchondral sclerosis may each predict progression among patients with hip osteoarthritis, show the results of a systematic review.

11-09-2019 | Rheumatology | News | Article

Cardiovascular safety may not substantially differ between tocilizumab and etanercept

Findings from the ENTRACTE trial suggest that the risk for major adverse cardiovascular events with tocilizumab may not be markedly greater than that with etanercept.

10-09-2019 | Rheumatology | News | Article

Support for TNF inhibitor–methotrexate combination in older RA patients

Rheumatoid arthritis patients aged 65 years or older experience a similar response to treatment with golimumab plus methotrexate compared with younger patients, suggests a post-hoc analysis of the GO-FURTHER trial.

10-09-2019 | Rheumatology | News | Article

FDA gives nod to ixekizumab for ankylosing spondylitis

Click through for more details on this announcement

09-09-2019 | Rheumatology | News | Article

Nintedanib receives FDA approval for SSc-ILD

Click through to read more about this approval

09-09-2019 | Rheumatology | News | Article

Denosumab plus high-dose teriparatide may improve postmenopausal osteoporosis

Combining denosumab with high-dose rather than standard-dose teriparatide results in greater increases in spine and hip bone mineral density in postmenopausal women with osteoporosis, phase IV study data show.

06-09-2019 | Rheumatology | News | Article

Optimal warfarin treatment intensity for VTE prevention after arthroplasty remains unclear

Low-intensity warfarin treatment has not demonstrated noninferiority to standard-intensity warfarin for the prevention of venous thromboembolism among older people undergoing hip or knee replacement surgery in a randomized controlled trial.

06-09-2019 | Rheumatology | News | Article

Inadequate glycemic testing prior to joint replacement surgery

A substantial proportion of patients undergoing total joint replacement do not receive a test for glycemic control prior to surgery, researchers report.

05-09-2019 | Rheumatology | News | Article

Pregnancy outcomes largely unaffected by DMARD exposure at conception in JIA

Juvenile idiopathic arthritis patients taking DMARDs at the time they conceive do not have an increased risk for major adverse pregnancy outcomes, research suggests.

04-09-2019 | Rheumatology | Main feed | Article

Preliminary trial results support further investigation of low-dose IL-2 therapy for SLE

The low-dose recombinant human interleukin IL-2 therapy aldesleukin has a favorable safety profile and may restore regulatory T-cell homeostasis in people with systemic lupus erythematosus, suggest findings from a proof-of-concept phase I/IIa clinical trial.

03-09-2019 | Rheumatology | News | Article

EMA recommends new measures to avoid methotrexate dosing errors

The EMA has issued new precautions for the avoidance of dosing errors when using methotrexate for the treatment of inflammatory disorders such as rheumatoid arthritis and psoriasis.

02-09-2019 | Rheumatology | News | Article

Alcohol consumption linked to axSpA progression

Alcohol consumption may be a modifiable risk factor for spinal structural damage among patients with axial spondyloarthritis, researchers report.

30-08-2019 | Rheumatology | News | Article

Observational data support long-term adalimumab use in polyarticular JIA

Adalimumab, used with or without concurrent methotrexate, appears to be well tolerated among children with polyarticular‐course juvenile idiopathic arthritis, 7-year data from the STRIVE registry show.

30-08-2019 | Rheumatology | News | Article

Extension study demonstrates stable long-term safety, efficacy profiles for peficitinib

The Janus kinase inhibitor peficitinib has demonstrated a consistent safety and efficacy profile over 2 years of follow-up among Japanese patients with rheumatoid arthritis, researchers report.

Image Credits